JOHN R - Center for Adaptive Neural Systems - Arizona State ...

More documents

Recommendations

Info

Denise Campagnolo, M.D. - Curriculum Vitae Page 10 of 22 24. A Blood Test for Multiple Sclerosis: Detection and Analysis of a Circulating Multiple Sclerosis Associated Antigen Co-Investigator 25. A Randomized, Double-Blinded, Placebo-Controlled, Multi-center Study to Evaluate the Efficacy and Safety of Atorvastatin in Patients with Clinically Isolated Syndrome and High Risk of Conversion to Multiple Sclerosis Co-Investigator 26. A Multi-Center, Double-Blind, Randomized Study Comparing the Combined Use of Interferon Beta-1a and Glatiramer Acetate to Either Agent Alone in Patients with Relapsing Remitting Multiple Sclerosis Co-Investigator 27. Biomarkers in Multiple Sclerosis Co-Investigator 28. A 12-month double-blind, randomized, multicenter, active-controlled, parallel-group study comparing the efficacy and safety of xxxxx mg and xxxxx mg xxxxx (xxxxx) administered orally once daily versus interferon β-1a (Avonex®) administered i.m. once weekly in patients with relapsing-remitting multiple sclerosis with optional Extension Phase Co-Investigator 29. A 24-month double-blind, randomized, multicenter, placebo-controlled, parallel-group study comparing the efficacy and safety of xxxxx mg and xxxxx mg xxxxx (xxxxx) administered orally once daily versus placebo in patients with relapsing-remitting multiple sclerosis Co-Investigator 30. A Phase 2 Randomized, Double-Blinded, Placebo-Controlled, Multi-Center Study of Subcutaneous Daclizumab® in Patients with Active, Relapsing Forms of Multiple Sclerosis Co-Investigator 31. A Phase II, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Safety, Tolerability and Efficacy Study on Add-on Cladribine Tablet Therapy with Rebif® New Formulation in Multiple Sclerosis Subjects with Active Disease Co-Investigator 32. Online Validation of Multiple Sclerosis International Quality of Life (MuSI-QoL) Questionnaire Co-Investigator 33. A Multi-Centered, Two Arm, Open Label Extension Study (to protocol xxxxx) to Evaluate the Long-Term Safety and Efficacy of Short-Term Induction Treatment with Mitoxantrone (Novantrone®) Preceding Treatment with Glatiramer Acetate (Copaxone®) vs. Chronic Treatment with Glatiramer Acetate Alone in Relapsing Forms of Multiple Sclerosis Co-Investigator Revised 6/9/2008
Denise Campagnolo, M.D. - Curriculum Vitae Page 11 of 22 34. Immunological Studies for a Multi-Centered, Randomized, Two-Arm, Open Label Study to Evaluate the Safety, Tolerability and Efficacy of Induction Treatment with Mitoxantrone (Novantrone®) Preceding Treatment with Glatiramer Acetate (Copaxone®) versus Chronic Treatment with Glatiramer Acetate Alone in Relapsing Forms of Multiple Sclerosis Co-Investigator 35. Double-blind, placebo-controlled, randomized, parallel-group Phase II study in subjects with relapsing forms of multiple sclerosis (MS) to evaluate the safety, tolerability, and effects of two doses of xxxxx over 24 weeks with a rater-blind MRI follow-up over 12 weeks Co-Investigator COMPLETED RESEARCH: 1. The Impact of CarePartner Stress in Multiple Sclerosis Co-Principal Investigator 2. A 24-Week, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Dose Finding, Safety, Tolerability, and Efficacy Study of the xxxxx in Subjects With Multiple Sclerosis With a 24-Week Double-Blind, Active Extension Phase Co-Investigator 3. Double-Blind, Placebo-Controlled, 21-Week, Parallel Group Study to Evaluate Safety and Efficacy of Oral xxxxx-SR (xxxxx mg B.I.D.) in Subjects with Multiple Sclerosis Co-Investigator 4. A Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Safety and Efficacy of xxxxx (xxxxx/xxxxx) in the Treatment of Pseudobulbar Affect in Patients with Multiple Sclerosis Co-Investigator 5. An Open-Label Multicenter Study to Assess the Safety of xxxxx (xxxxx/xxxxx) in the Treatment of Patients with Pseudobulbar Affect Co-Investigator 6. Randomized, Double-Blind, Placebo-Controlled Study to Compare the Effects of Different Dose Regimens of IGIV-Chromatography (IGIV-C), 10% Treatment on Relapses in Patients with Relapsing Remitting Multiple Sclerosis Co-Investigator 7. Phase I Trial of Immunotherapy with xxxxx Alone or Combined with Atorvastatin in Patients with Multiple Sclerosis Co-Investigator 8. An Exploratory Study of Blood Markers of Disease Activity in Multiple Sclerosis Co-Investigator Revised 6/9/2008
Page 1 and 2: Denise I. Campagnolo, M.D. Faculty,
Page 3 and 4: Denise Campagnolo, M.D. - Curriculu
Page 9: Denise Campagnolo, M.D. - Curriculu

JOHN R - Center for Adaptive Neural Systems - Arizona State ...

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?